亚宝药业集团股份有限公司 关于回购股份比例达到1%暨回购进展公告

Group 1 - The company has approved a share repurchase plan at the 2024 annual shareholders' meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a maximum price of RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of October 30, 2025, the company has repurchased 8,000,000 shares, accounting for 1.14% of the total share capital, with a total payment of RMB 52,151,912, at a maximum price of RMB 6.65 and a minimum price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the share repurchase [2]